Showing 1851-1860 of 3145 results for "".
- Female Authorship Rises in Facial Plastic Surgery Literature, But Gaps Remainhttps://modernaesthetics.com/news/female-authorship-rises-in-facial-plastic-surgery-literature-but-gaps-remain/2486534/A cross-sectional bibliometric analysis published in Facial Plastic Surgery & Aesthetic Medicine examined trends in female authorship across facial plastic surgery literature from 2007 to 2022. The study evaluated 6,921 original research articles from 3 journals, assessing authorship
- Female Authorship Rises in Facial Plastic Surgery Literature, But Gaps Remainhttps://modernaesthetics.com/news/female-authorship-rises-in-facial-plastic-surgery-literature-but-gaps-remain/2486533/A cross-sectional bibliometric analysis published in Facial Plastic Surgery & Aesthetic Medicine examined trends in female authorship across facial plastic surgery literature from 2007 to 2022. The study evaluated 6,921 original research articles from 3 journals, assessing authorship
- Case Report Describes Dual-Phase CL Code for Facial Rejuvenationhttps://modernaesthetics.com/news/case-report-describes-dual-phase-cl-code-for-facial-rejuvenation/2486484/A case report in the April 2026 issue of Journal of Cosmetic Dermatology described a dual-phase injectable approach to facial rejuvenation that combined contour restoration with ligamentous support using a polycaprolactone-based collagen stimulator. The authors termed the method the “CL
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- AAD 2026: New Study Highlights Dual-Action Antioxidant Serum for UV-Induced Skin Protectionhttps://modernaesthetics.com/news/aad-2026-new-study-highlights-dual-action-antioxidant-serum-for-uv-induced-skin-protection/2486463/New research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting highlights the potential of a multifunctional antioxidant serum, AOX2.0, to protect human skin from ultraviolet (UV)-induced damage while supporting epidermal recovery. The study examined how oxidative stress
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://modernaesthetics.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- AAD 2026: Allergan Aesthetics Highlights TrenibotE Data and GLP-1 RA Patient Trendshttps://modernaesthetics.com/news/aad-2026-allergan-aesthetics-highlights-trenibote-data-and-glp-1-patient-trends/2486432/Allergan Aesthetics, an AbbVie company, presented four posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, including new findings on repeat treatment with investigational trenibotulinumtoxinE (TrenibotE) and insights into aesthetic trends among patients r
- AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patientshttps://modernaesthetics.com/news/aad-2026-survey-highlights-facial-concerns-among-glp-1-weight-loss-patients/2486397/A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un